For most of the last three years, the amylin story in obesity medicine has been a peptide story. Novo Nordisk built cagrilintide, Zealand Pharma and Roche are pushing petrelintide into Phase 3, and Eli Lilly is developing eloralintide. On November 6, a Boston- and Shanghai-based company called Eccogene said it would show up at ObesityWeek 2026 with something different: an amylin agonist that is not a peptide at all, but an oral small molecule called ECC1542. The announcement is short on data, and that matters as much as the idea itself.
Eccogene said a poster titled “A Small Molecule Amylin Receptor and Calcitonin Receptor Agonist for Treating Obesity” will be presented on November 14, from 7:30 to 8:30 p.m. Eastern, in the exhibit hall at the Gaylord National Resort in National Harbor, Maryland. The Obesity Society’s annual meeting runs through November 17. The presenter is Jingye Zhou, the company’s chief executive, and the work is described as preclinical. The release gives no weight-loss figures, no food-intake numbers and no indication of which animal species were studied.
Why a Small-Molecule Amylin Agonist Is a Big Claim
Amylin is a peptide hormone released alongside insulin, and drugs that mimic it act on a family of receptors. Eccogene’s release names the targets as the amylin receptors AMY1R, AMY2R and AMY3R, plus the calcitonin receptor, and describes the general biology that has made the pathway attractive: appetite suppression and satiety through the brain, lower glucagon secretion and slower stomach emptying. Those are descriptions of the pathway, not results for ECC1542.
The difficulty is structural. Amylin receptors are not simply isolated proteins but complexes involving the calcitonin receptor and accessory proteins called receptor activity-modifying proteins. Peptide drugs can engage these receptors through interactions that may be difficult to reproduce with much smaller, non-peptide molecules. That makes the chemistry challenging, although it does not make successful small-molecule agonism impossible.
There is an important distinction between an oral amylin-targeting drug and an oral small-molecule amylin drug. Novo Nordisk has already tested oral amycretin, now called zenagamtide, in humans. It is a peptide-based co-agonist targeting GLP-1 and amylin receptors, with published Phase 1 results in 2025 and an oral Phase 2 diabetes study published in August 2026.
Eccogene is therefore not introducing the first oral approach to amylin biology. Its proposed distinction is using a non-peptide small molecule rather than an orally formulated peptide.
That distinction matters because small molecules can offer different manufacturing, formulation and combination possibilities. Whether ECC1542 actually provides those advantages remains to be demonstrated.
The release describes the biology of amylin receptors, not a demonstrated weight-loss effect of ECC1542.
Eccogene’s pitch for pursuing the compound is practical as well as pharmacological. The company says an oral small molecule could simplify storage and logistics and make combination with other oral treatments more flexible. In a market where oral GLP-1 drugs are already becoming commercially important, the appeal of an oral amylin partner is easy to understand.
Zhou said ECC1542 “may offer a significant therapeutic opportunity” for obesity and related metabolic conditions. That remains a development hypothesis, not a clinical conclusion.
The Peptide Amylin Field It Is Trying to Leapfrog
The established injectable competitors are considerably further along and have human clinical results.
In October, Zealand Pharma reported Phase 2 ZUPREME-2 results for petrelintide, its once-weekly amylin analog, in 220 adults with overweight or obesity and type 2 diabetes. Mean weight loss reached up to 9.2% at week 28 versus 2.0% with placebo, according to company-reported topline results. Discontinuations due to gastrointestinal adverse events were 1.9% with petrelintide versus 1.7% with placebo.
Those figures come from the best-performing treatment arm in a Phase 2 study, not a completed Phase 3 trial. Nevertheless, they provide human efficacy and tolerability evidence that ECC1542 does not yet have.
Zealand and Roche have started a Phase 3a program expected to enroll approximately 7,000 participants, and they are developing combination approaches involving petrelintide and the GLP-1 agonist enicepatide. We covered that strategy in our analysis of the petrelintide and enicepatide combination.
Lilly’s eloralintide amylin program points in the same direction: the industry is betting that amylin biology can offer weight-loss benefits and potentially different tolerability characteristics from GLP-1 treatment alone.
Smaller companies are also entering the field. Viking Therapeutics reported on October 28 that its dual amylin and calcitonin receptor agonist VK3019 was progressing through a Phase 1 single-ascending-dose study. Viking expected to begin a 28-day multiple-ascending-dose study in the first quarter of 2027.
And Novo’s oral zenagamtide demonstrates that amylin-targeting peptides are not confined to injections. Its human data make the competitive landscape more complicated than a simple battle between injectable peptides and a new pill.
The difference is that these programs have reached human clinical testing. ECC1542 is still at the preclinical stage, with its first detailed public presentation scheduled for November 14.
Oral amylin biology is already being tested in humans. Eccogene’s harder experiment is whether a non-peptide molecule can do the job.
Eccogene Has Done the Small-Molecule Trick Once Before
The company’s track record is the main reason to pay attention.
In November 2023, AstraZeneca licensed Eccogene’s ECC5004, an investigational once-daily oral small-molecule GLP-1 receptor agonist. The agreement included $185 million upfront, up to $1.825 billion in potential additional milestones and royalties.
AstraZeneca received exclusive development and commercialization rights outside China, where Eccogene retained co-development and co-commercialization rights.
That transaction showed that a major pharmaceutical company was willing to make a substantial financial commitment to Eccogene’s small-molecule receptor-agonist research. It also gave Eccogene experience working with a global drug developer.
But GLP-1 is not amylin. The success of one receptor-targeting strategy does not establish that the chemistry will translate to a different receptor family.
Oral small-molecule GLP-1 drugs have already provided clinical and commercial examples of what non-peptide receptor agonists can achieve. Lilly’s orforglipron is one example. That precedent makes the ECC1542 approach interesting, but it does not validate the candidate itself.
Translating the small-molecule playbook to amylin and calcitonin receptors is a separate scientific problem.
Eccogene says it has three clinical-stage drug candidates and multiple preclinical programs. ECC1542 belongs to the latter group, and the November 6 announcement does not provide the quantitative evidence needed to judge its effectiveness.
What the ObesityWeek Poster Needs to Show
Because the announcement contains no numerical experimental results, the poster itself will carry the weight of the story.
The first question is receptor activity. Does ECC1542 meaningfully activate AMY1R, AMY2R, AMY3R and the calcitonin receptor, and how does its activity vary across those targets?
That balance matters because different amylin and calcitonin receptor agonists may have different pharmacological profiles. The detailed receptor results will help researchers determine whether ECC1542 has a distinctive mechanism or simply belongs to an increasingly crowded class.
The second question is whether the compound reduces food intake and body weight in animals, and in which species. Rodent experiments are a useful early step, but they cannot reliably predict the magnitude, durability or safety of weight loss in people.
The third question is oral exposure. A molecule designed to be swallowed must reach sufficient concentrations in the body and sustain useful activity without unacceptable toxicity.
Outside researchers will want to see data on oral bioavailability, dose-response relationships, pharmacokinetics and the duration of receptor engagement.
The fourth question concerns safety and selectivity. Preclinical safety findings, including tolerability and possible off-target effects, would help establish whether the molecule has a plausible path toward human testing.
Finally, the poster needs to distinguish observed results from the proposed benefits of oral administration. Easier storage, greater adherence and simpler combination therapy may be reasonable development goals, but none is proven for ECC1542 merely because it is a small molecule.
Eccogene said the poster will become available on its website after the conference concludes. That is the next opportunity for independent scrutiny.
Until then, there is no publicly disclosed human exposure, clinical weight-loss result or established dosing schedule for ECC1542.
A poster can establish whether an interesting chemical idea deserves further testing. It cannot establish that the resulting drug works in patients.
Why This Matters Beyond One Poster
The obesity field’s next phase is about combinations and convenience, not simply larger headline weight-loss percentages.
Drug developers are investigating whether activating more than one metabolic pathway can provide better outcomes, improve tolerability or support different treatment schedules.
Amylin has become an important part of that search because it works through biological mechanisms that overlap with, but are not identical to, those of GLP-1.
A credible oral small-molecule amylin agonist could potentially expand the ways researchers combine these pathways. It might allow new oral regimens or different manufacturing and distribution approaches from injectable peptide medicines.
But combining an oral amylin candidate with an oral GLP-1 drug in a single tablet would introduce additional formulation, pharmacokinetic and safety questions. Such a combination has not been demonstrated for ECC1542.
The competitive challenge is also substantial. Peptide amylin analogs already have published human studies, established clinical development programs and large pharmaceutical partners. Oral peptide-based approaches, including zenagamtide, have reached human trials as well.
ECC1542 has a different chemical strategy, but the public evidence is currently far less developed.
That is the central distinction investors and researchers should keep in mind. A compound can be chemically innovative without being clinically effective. It can activate the desired receptors in laboratory experiments without producing useful or tolerable weight loss in patients.
There are still several stages between a promising preclinical profile and a treatment that can be prescribed.
The Bottom Line on ECC1542
Eccogene is staking a claim in a crowded and promising metabolic pathway using a more difficult chemical approach: an oral non-peptide small molecule designed to activate amylin and calcitonin receptors.
The idea is worth watching because of its potential implications for oral obesity treatments and because Eccogene has previously licensed a small-molecule GLP-1 program to AstraZeneca.
Neither fact establishes that ECC1542 will work.
On November 14, the field is scheduled to see its first detailed presentation of the candidate’s preclinical data. The important questions will concern receptor activity, animal outcomes, oral exposure and early safety.
The honest reading is that Eccogene has announced an intriguing non-peptide approach to amylin biology, but it has not yet publicly demonstrated clinical benefit.
There is an enormous difference between designing an amylin pill and proving that an amylin pill works. ECC1542 is still on the first side of that divide.
Sources
- Eccogene / GlobeNewswire — Eccogene to Present Preclinical Data of Small Molecule Amylin and Calcitonin Receptor Agonist ECC1542 at ObesityWeek 2026, November 6, 2026.
- Zealand Pharma / GlobeNewswire — Zealand Pharma Announces Positive Phase 2 ZUPREME-2 Topline Results for Petrelintide, October 7, 2026.
- Viking Therapeutics — Viking Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update, October 28, 2026.
- AstraZeneca — AstraZeneca Licenses Novel Agent for Cardiometabolic Conditions and Obesity, November 9, 2023.
- The Lancet / PubMed — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Amycretin: A First-in-Human Phase 1 Trial, July 2025.
- The Lancet / PubMed — Efficacy and Safety of Once-Daily Oral Zenagamtide in Adults With Type 2 Diabetes: A Phase 2 Trial, August 2026.
- ObesityWeek — ObesityWeek 2026 Scientific Program and Poster Information.
